NEW YORK(GenomeWeb) – With sales growing at a double-digit clip, Swiss proteomics firm Biognosys is carving out a market for its mass spec-based protein quantitation services.

This year, the company, which specializes in development of multiple-reaction monitoring and data independent acquisition mass spec assays, will report roughly CHF 2 million ($2.1 million) in revenues, up 50 percent from around CHF $1.3 million in 2013, CEO Oliver Rinner told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.